nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Sibutramine—obesity	0.0872	0.27	CbGbCtD
Solifenacin—CYP3A4—Benzphetamine—obesity	0.0661	0.204	CbGbCtD
Solifenacin—CYP3A4—Bupropion—obesity	0.0562	0.174	CbGbCtD
Solifenacin—CYP3A4—Orlistat—obesity	0.0458	0.142	CbGbCtD
Solifenacin—CYP3A4—Cimetidine—obesity	0.0413	0.128	CbGbCtD
Solifenacin—CYP3A4—Topiramate—obesity	0.027	0.0835	CbGbCtD
Solifenacin—Benazepril—MTHFR—obesity	0.0026	0.551	CrCbGaD
Solifenacin—Benazepril—ACE—obesity	0.00212	0.449	CrCbGaD
Solifenacin—Liver function test abnormal—Sibutramine—obesity	0.00125	0.00327	CcSEcCtD
Solifenacin—Anaphylactic shock—Cimetidine—obesity	0.00124	0.00326	CcSEcCtD
Solifenacin—Dry skin—Sibutramine—obesity	0.00124	0.00325	CcSEcCtD
Solifenacin—Dizziness—Phendimetrazine—obesity	0.00122	0.00319	CcSEcCtD
Solifenacin—Tachycardia—Cimetidine—obesity	0.00121	0.00318	CcSEcCtD
Solifenacin—Influenza—Orlistat—obesity	0.00121	0.00317	CcSEcCtD
Solifenacin—Delirium—Topiramate—obesity	0.0012	0.00315	CcSEcCtD
Solifenacin—Nausea—Benzphetamine—obesity	0.0012	0.00314	CcSEcCtD
Solifenacin—Urticaria—Phentermine—obesity	0.00119	0.00313	CcSEcCtD
Solifenacin—Muscular weakness—Sibutramine—obesity	0.00119	0.00313	CcSEcCtD
Solifenacin—Abdominal pain—Phentermine—obesity	0.00119	0.00311	CcSEcCtD
Solifenacin—Influenza—Sibutramine—obesity	0.00117	0.00306	CcSEcCtD
Solifenacin—Somnolence—Diethylpropion—obesity	0.00116	0.00305	CcSEcCtD
Solifenacin—Hypersensitivity—Phenylpropanolamine—obesity	0.00116	0.00303	CcSEcCtD
Solifenacin—Headache—Phendimetrazine—obesity	0.00115	0.00302	CcSEcCtD
Solifenacin—Dyspepsia—Diethylpropion—obesity	0.00115	0.00302	CcSEcCtD
Solifenacin—Gastrooesophageal reflux disease—Topiramate—obesity	0.00115	0.003	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Diethylpropion—obesity	0.00113	0.00296	CcSEcCtD
Solifenacin—Urinary retention—Bupropion—obesity	0.00112	0.00294	CcSEcCtD
Solifenacin—Constipation—Diethylpropion—obesity	0.00112	0.00293	CcSEcCtD
Solifenacin—Drug interaction—Topiramate—obesity	0.00112	0.00292	CcSEcCtD
Solifenacin—Somnolence—Cimetidine—obesity	0.00111	0.0029	CcSEcCtD
Solifenacin—Dysuria—Sibutramine—obesity	0.00109	0.00287	CcSEcCtD
Solifenacin—Nausea—Phendimetrazine—obesity	0.00109	0.00286	CcSEcCtD
Solifenacin—Dry skin—Bupropion—obesity	0.00108	0.00283	CcSEcCtD
Solifenacin—Asthenia—Phentermine—obesity	0.00108	0.00283	CcSEcCtD
Solifenacin—Feeling abnormal—Diethylpropion—obesity	0.00108	0.00282	CcSEcCtD
Solifenacin—Infestation—Orlistat—obesity	0.00108	0.00282	CcSEcCtD
Solifenacin—Infestation NOS—Orlistat—obesity	0.00108	0.00282	CcSEcCtD
Solifenacin—Abdominal pain upper—Bupropion—obesity	0.00108	0.00282	CcSEcCtD
Solifenacin—Depression—Orlistat—obesity	0.00107	0.00281	CcSEcCtD
Solifenacin—Fatigue—Cimetidine—obesity	0.00107	0.00281	CcSEcCtD
Solifenacin—Constipation—Cimetidine—obesity	0.00106	0.00279	CcSEcCtD
Solifenacin—Renal failure—Orlistat—obesity	0.00106	0.00277	CcSEcCtD
Solifenacin—Urinary tract infection—Orlistat—obesity	0.00105	0.00274	CcSEcCtD
Solifenacin—Muscular weakness—Bupropion—obesity	0.00104	0.00273	CcSEcCtD
Solifenacin—Depression—Sibutramine—obesity	0.00104	0.00272	CcSEcCtD
Solifenacin—Urticaria—Diethylpropion—obesity	0.00104	0.00272	CcSEcCtD
Solifenacin—Dizziness—Phenylpropanolamine—obesity	0.00104	0.00272	CcSEcCtD
Solifenacin—Feeling abnormal—Cimetidine—obesity	0.00102	0.00269	CcSEcCtD
Solifenacin—Renal failure—Sibutramine—obesity	0.00102	0.00269	CcSEcCtD
Solifenacin—Influenza—Bupropion—obesity	0.00102	0.00267	CcSEcCtD
Solifenacin—Hepatobiliary disease—Orlistat—obesity	0.00102	0.00267	CcSEcCtD
Solifenacin—Urinary tract infection—Sibutramine—obesity	0.00101	0.00266	CcSEcCtD
Solifenacin—Cystitis noninfective—Topiramate—obesity	0.00101	0.00265	CcSEcCtD
Solifenacin—Cystitis—Topiramate—obesity	0.000999	0.00262	CcSEcCtD
Solifenacin—Vomiting—Phenylpropanolamine—obesity	0.000998	0.00262	CcSEcCtD
Solifenacin—Dizziness—Phentermine—obesity	0.000994	0.00261	CcSEcCtD
Solifenacin—Rash—Phenylpropanolamine—obesity	0.00099	0.0026	CcSEcCtD
Solifenacin—Dermatitis—Phenylpropanolamine—obesity	0.000989	0.00259	CcSEcCtD
Solifenacin—Pharyngitis—Orlistat—obesity	0.000959	0.00252	CcSEcCtD
Solifenacin—Dry eye—Topiramate—obesity	0.000955	0.00251	CcSEcCtD
Solifenacin—Vomiting—Phentermine—obesity	0.000955	0.0025	CcSEcCtD
Solifenacin—Urinary tract disorder—Orlistat—obesity	0.000954	0.0025	CcSEcCtD
Solifenacin—Dysuria—Bupropion—obesity	0.000953	0.0025	CcSEcCtD
Solifenacin—Oedema peripheral—Orlistat—obesity	0.000952	0.0025	CcSEcCtD
Solifenacin—Urethral disorder—Orlistat—obesity	0.000947	0.00248	CcSEcCtD
Solifenacin—Rash—Phentermine—obesity	0.000947	0.00248	CcSEcCtD
Solifenacin—Dermatitis—Phentermine—obesity	0.000946	0.00248	CcSEcCtD
Solifenacin—Headache—Phentermine—obesity	0.000941	0.00247	CcSEcCtD
Solifenacin—Bladder pain—Topiramate—obesity	0.000935	0.00245	CcSEcCtD
Solifenacin—Nausea—Phenylpropanolamine—obesity	0.000933	0.00245	CcSEcCtD
Solifenacin—Pharyngitis—Sibutramine—obesity	0.000928	0.00243	CcSEcCtD
Solifenacin—Oedema peripheral—Sibutramine—obesity	0.000921	0.00242	CcSEcCtD
Solifenacin—Hypersensitivity—Cimetidine—obesity	0.000916	0.0024	CcSEcCtD
Solifenacin—Infestation NOS—Bupropion—obesity	0.000908	0.00238	CcSEcCtD
Solifenacin—Infestation—Bupropion—obesity	0.000908	0.00238	CcSEcCtD
Solifenacin—Nausea—Phentermine—obesity	0.000892	0.00234	CcSEcCtD
Solifenacin—Asthenia—Cimetidine—obesity	0.000892	0.00234	CcSEcCtD
Solifenacin—Urinary tract infection—Bupropion—obesity	0.000883	0.00232	CcSEcCtD
Solifenacin—Eye disorder—Sibutramine—obesity	0.000874	0.00229	CcSEcCtD
Solifenacin—Immune system disorder—Orlistat—obesity	0.000873	0.00229	CcSEcCtD
Solifenacin—Mediastinal disorder—Orlistat—obesity	0.000871	0.00228	CcSEcCtD
Solifenacin—Dizziness—Diethylpropion—obesity	0.000864	0.00227	CcSEcCtD
Solifenacin—Angiopathy—Sibutramine—obesity	0.000849	0.00223	CcSEcCtD
Solifenacin—Mental disorder—Orlistat—obesity	0.000847	0.00222	CcSEcCtD
Solifenacin—Immune system disorder—Sibutramine—obesity	0.000845	0.00222	CcSEcCtD
Solifenacin—Malnutrition—Orlistat—obesity	0.000841	0.00221	CcSEcCtD
Solifenacin—Vomiting—Diethylpropion—obesity	0.000831	0.00218	CcSEcCtD
Solifenacin—Rash—Diethylpropion—obesity	0.000824	0.00216	CcSEcCtD
Solifenacin—Dysgeusia—Orlistat—obesity	0.000824	0.00216	CcSEcCtD
Solifenacin—Dermatitis—Diethylpropion—obesity	0.000823	0.00216	CcSEcCtD
Solifenacin—Dizziness—Cimetidine—obesity	0.000822	0.00216	CcSEcCtD
Solifenacin—Headache—Diethylpropion—obesity	0.000819	0.00215	CcSEcCtD
Solifenacin—Malnutrition—Sibutramine—obesity	0.000814	0.00213	CcSEcCtD
Solifenacin—Hallucination—Bupropion—obesity	0.000811	0.00213	CcSEcCtD
Solifenacin—Pharyngitis—Bupropion—obesity	0.000809	0.00212	CcSEcCtD
Solifenacin—Urinary tract disorder—Bupropion—obesity	0.000805	0.00211	CcSEcCtD
Solifenacin—Oedema peripheral—Bupropion—obesity	0.000803	0.00211	CcSEcCtD
Solifenacin—Connective tissue disorder—Bupropion—obesity	0.000801	0.0021	CcSEcCtD
Solifenacin—Urethral disorder—Bupropion—obesity	0.000799	0.0021	CcSEcCtD
Solifenacin—Dysgeusia—Sibutramine—obesity	0.000797	0.00209	CcSEcCtD
Solifenacin—Vision blurred—Orlistat—obesity	0.000793	0.00208	CcSEcCtD
Solifenacin—Vomiting—Cimetidine—obesity	0.000791	0.00207	CcSEcCtD
Solifenacin—Rash—Cimetidine—obesity	0.000784	0.00206	CcSEcCtD
Solifenacin—Dermatitis—Cimetidine—obesity	0.000783	0.00205	CcSEcCtD
Solifenacin—Headache—Cimetidine—obesity	0.000779	0.00204	CcSEcCtD
Solifenacin—Nausea—Diethylpropion—obesity	0.000776	0.00204	CcSEcCtD
Solifenacin—Erythema multiforme—Bupropion—obesity	0.000771	0.00202	CcSEcCtD
Solifenacin—Angioedema—Orlistat—obesity	0.000769	0.00202	CcSEcCtD
Solifenacin—Vision blurred—Sibutramine—obesity	0.000767	0.00201	CcSEcCtD
Solifenacin—Eye disorder—Bupropion—obesity	0.000762	0.002	CcSEcCtD
Solifenacin—Cardiac disorder—Bupropion—obesity	0.000757	0.00198	CcSEcCtD
Solifenacin—Angioedema—Sibutramine—obesity	0.000744	0.00195	CcSEcCtD
Solifenacin—Palpitations—Orlistat—obesity	0.000743	0.00195	CcSEcCtD
Solifenacin—Angiopathy—Bupropion—obesity	0.00074	0.00194	CcSEcCtD
Solifenacin—Nausea—Cimetidine—obesity	0.000739	0.00194	CcSEcCtD
Solifenacin—Immune system disorder—Bupropion—obesity	0.000736	0.00193	CcSEcCtD
Solifenacin—Mediastinal disorder—Bupropion—obesity	0.000735	0.00193	CcSEcCtD
Solifenacin—Cough—Orlistat—obesity	0.000734	0.00193	CcSEcCtD
Solifenacin—Palpitations—Sibutramine—obesity	0.00072	0.00189	CcSEcCtD
Solifenacin—Mental disorder—Bupropion—obesity	0.000714	0.00187	CcSEcCtD
Solifenacin—Urinary retention—Topiramate—obesity	0.000714	0.00187	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000711	0.00187	CcSEcCtD
Solifenacin—Cough—Sibutramine—obesity	0.00071	0.00186	CcSEcCtD
Solifenacin—Malnutrition—Bupropion—obesity	0.00071	0.00186	CcSEcCtD
Solifenacin—Hypertension—Sibutramine—obesity	0.000703	0.00184	CcSEcCtD
Solifenacin—Dry mouth—Orlistat—obesity	0.0007	0.00184	CcSEcCtD
Solifenacin—Dysgeusia—Bupropion—obesity	0.000695	0.00182	CcSEcCtD
Solifenacin—Liver function test abnormal—Topiramate—obesity	0.000693	0.00182	CcSEcCtD
Solifenacin—Anaphylactic shock—Orlistat—obesity	0.000687	0.0018	CcSEcCtD
Solifenacin—Abdominal pain upper—Topiramate—obesity	0.000686	0.0018	CcSEcCtD
Solifenacin—Infection—Orlistat—obesity	0.000682	0.00179	CcSEcCtD
Solifenacin—Dry mouth—Sibutramine—obesity	0.000678	0.00178	CcSEcCtD
Solifenacin—Nervous system disorder—Orlistat—obesity	0.000673	0.00177	CcSEcCtD
Solifenacin—Confusional state—Sibutramine—obesity	0.00067	0.00176	CcSEcCtD
Solifenacin—Vision blurred—Bupropion—obesity	0.000669	0.00175	CcSEcCtD
Solifenacin—Skin disorder—Orlistat—obesity	0.000667	0.00175	CcSEcCtD
Solifenacin—Anaphylactic shock—Sibutramine—obesity	0.000664	0.00174	CcSEcCtD
Solifenacin—Muscular weakness—Topiramate—obesity	0.000662	0.00174	CcSEcCtD
Solifenacin—Infection—Sibutramine—obesity	0.00066	0.00173	CcSEcCtD
Solifenacin—Angioedema—Bupropion—obesity	0.000649	0.0017	CcSEcCtD
Solifenacin—Tachycardia—Sibutramine—obesity	0.000649	0.0017	CcSEcCtD
Solifenacin—Skin disorder—Sibutramine—obesity	0.000645	0.00169	CcSEcCtD
Solifenacin—Palpitations—Bupropion—obesity	0.000627	0.00164	CcSEcCtD
Solifenacin—Cough—Bupropion—obesity	0.000619	0.00162	CcSEcCtD
Solifenacin—Hypertension—Bupropion—obesity	0.000613	0.00161	CcSEcCtD
Solifenacin—Dysuria—Topiramate—obesity	0.000607	0.00159	CcSEcCtD
Solifenacin—Dyspepsia—Orlistat—obesity	0.000604	0.00158	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.0006	0.00157	CcSEcCtD
Solifenacin—Decreased appetite—Orlistat—obesity	0.000597	0.00157	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Orlistat—obesity	0.000593	0.00155	CcSEcCtD
Solifenacin—Fatigue—Orlistat—obesity	0.000592	0.00155	CcSEcCtD
Solifenacin—Dry mouth—Bupropion—obesity	0.000591	0.00155	CcSEcCtD
Solifenacin—Somnolence—Sibutramine—obesity	0.000591	0.00155	CcSEcCtD
Solifenacin—Dyspepsia—Sibutramine—obesity	0.000585	0.00153	CcSEcCtD
Solifenacin—Confusional state—Bupropion—obesity	0.000584	0.00153	CcSEcCtD
Solifenacin—Anaphylactic shock—Bupropion—obesity	0.000579	0.00152	CcSEcCtD
Solifenacin—Infestation NOS—Topiramate—obesity	0.000579	0.00152	CcSEcCtD
Solifenacin—Infestation—Topiramate—obesity	0.000579	0.00152	CcSEcCtD
Solifenacin—Decreased appetite—Sibutramine—obesity	0.000578	0.00151	CcSEcCtD
Solifenacin—Depression—Topiramate—obesity	0.000577	0.00151	CcSEcCtD
Solifenacin—Infection—Bupropion—obesity	0.000576	0.00151	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Sibutramine—obesity	0.000574	0.0015	CcSEcCtD
Solifenacin—Renal failure—Topiramate—obesity	0.000569	0.00149	CcSEcCtD
Solifenacin—Constipation—Sibutramine—obesity	0.000568	0.00149	CcSEcCtD
Solifenacin—Nervous system disorder—Bupropion—obesity	0.000568	0.00149	CcSEcCtD
Solifenacin—Feeling abnormal—Orlistat—obesity	0.000566	0.00148	CcSEcCtD
Solifenacin—Tachycardia—Bupropion—obesity	0.000565	0.00148	CcSEcCtD
Solifenacin—Skin disorder—Bupropion—obesity	0.000563	0.00148	CcSEcCtD
Solifenacin—Urinary tract infection—Topiramate—obesity	0.000562	0.00147	CcSEcCtD
Solifenacin—Gastrointestinal pain—Orlistat—obesity	0.000561	0.00147	CcSEcCtD
Solifenacin—Feeling abnormal—Sibutramine—obesity	0.000548	0.00144	CcSEcCtD
Solifenacin—Urticaria—Orlistat—obesity	0.000545	0.00143	CcSEcCtD
Solifenacin—Gastrointestinal pain—Sibutramine—obesity	0.000543	0.00142	CcSEcCtD
Solifenacin—Abdominal pain—Orlistat—obesity	0.000543	0.00142	CcSEcCtD
Solifenacin—Urticaria—Sibutramine—obesity	0.000528	0.00138	CcSEcCtD
Solifenacin—Abdominal pain—Sibutramine—obesity	0.000525	0.00138	CcSEcCtD
Solifenacin—Hallucination—Topiramate—obesity	0.000517	0.00136	CcSEcCtD
Solifenacin—Pharyngitis—Topiramate—obesity	0.000516	0.00135	CcSEcCtD
Solifenacin—Somnolence—Bupropion—obesity	0.000515	0.00135	CcSEcCtD
Solifenacin—Urinary tract disorder—Topiramate—obesity	0.000513	0.00135	CcSEcCtD
Solifenacin—Oedema peripheral—Topiramate—obesity	0.000512	0.00134	CcSEcCtD
Solifenacin—Connective tissue disorder—Topiramate—obesity	0.00051	0.00134	CcSEcCtD
Solifenacin—Dyspepsia—Bupropion—obesity	0.00051	0.00134	CcSEcCtD
Solifenacin—Urethral disorder—Topiramate—obesity	0.000509	0.00134	CcSEcCtD
Solifenacin—Hypersensitivity—Orlistat—obesity	0.000506	0.00133	CcSEcCtD
Solifenacin—Decreased appetite—Bupropion—obesity	0.000504	0.00132	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Bupropion—obesity	0.0005	0.00131	CcSEcCtD
Solifenacin—Fatigue—Bupropion—obesity	0.000499	0.00131	CcSEcCtD
Solifenacin—Constipation—Bupropion—obesity	0.000495	0.0013	CcSEcCtD
Solifenacin—Asthenia—Orlistat—obesity	0.000493	0.00129	CcSEcCtD
Solifenacin—Erythema multiforme—Topiramate—obesity	0.000491	0.00129	CcSEcCtD
Solifenacin—Hypersensitivity—Sibutramine—obesity	0.00049	0.00128	CcSEcCtD
Solifenacin—Pruritus—Orlistat—obesity	0.000486	0.00127	CcSEcCtD
Solifenacin—Eye disorder—Topiramate—obesity	0.000485	0.00127	CcSEcCtD
Solifenacin—Cardiac disorder—Topiramate—obesity	0.000482	0.00126	CcSEcCtD
Solifenacin—Feeling abnormal—Bupropion—obesity	0.000477	0.00125	CcSEcCtD
Solifenacin—Asthenia—Sibutramine—obesity	0.000477	0.00125	CcSEcCtD
Solifenacin—Gastrointestinal pain—Bupropion—obesity	0.000474	0.00124	CcSEcCtD
Solifenacin—Angiopathy—Topiramate—obesity	0.000471	0.00124	CcSEcCtD
Solifenacin—Pruritus—Sibutramine—obesity	0.00047	0.00123	CcSEcCtD
Solifenacin—Immune system disorder—Topiramate—obesity	0.000469	0.00123	CcSEcCtD
Solifenacin—Mediastinal disorder—Topiramate—obesity	0.000468	0.00123	CcSEcCtD
Solifenacin—Urticaria—Bupropion—obesity	0.00046	0.00121	CcSEcCtD
Solifenacin—Abdominal pain—Bupropion—obesity	0.000458	0.0012	CcSEcCtD
Solifenacin—Mental disorder—Topiramate—obesity	0.000455	0.00119	CcSEcCtD
Solifenacin—Dizziness—Orlistat—obesity	0.000454	0.00119	CcSEcCtD
Solifenacin—Malnutrition—Topiramate—obesity	0.000452	0.00119	CcSEcCtD
Solifenacin—Dysgeusia—Topiramate—obesity	0.000443	0.00116	CcSEcCtD
Solifenacin—Dizziness—Sibutramine—obesity	0.000439	0.00115	CcSEcCtD
Solifenacin—Vomiting—Orlistat—obesity	0.000437	0.00114	CcSEcCtD
Solifenacin—Rash—Orlistat—obesity	0.000433	0.00114	CcSEcCtD
Solifenacin—Dermatitis—Orlistat—obesity	0.000433	0.00113	CcSEcCtD
Solifenacin—Headache—Orlistat—obesity	0.00043	0.00113	CcSEcCtD
Solifenacin—Hypersensitivity—Bupropion—obesity	0.000427	0.00112	CcSEcCtD
Solifenacin—Vision blurred—Topiramate—obesity	0.000426	0.00112	CcSEcCtD
Solifenacin—Vomiting—Sibutramine—obesity	0.000422	0.00111	CcSEcCtD
Solifenacin—Rash—Sibutramine—obesity	0.000419	0.0011	CcSEcCtD
Solifenacin—Dermatitis—Sibutramine—obesity	0.000419	0.0011	CcSEcCtD
Solifenacin—Headache—Sibutramine—obesity	0.000416	0.00109	CcSEcCtD
Solifenacin—Asthenia—Bupropion—obesity	0.000416	0.00109	CcSEcCtD
Solifenacin—Pruritus—Bupropion—obesity	0.00041	0.00107	CcSEcCtD
Solifenacin—Nausea—Orlistat—obesity	0.000408	0.00107	CcSEcCtD
Solifenacin—Palpitations—Topiramate—obesity	0.0004	0.00105	CcSEcCtD
Solifenacin—Nausea—Sibutramine—obesity	0.000395	0.00103	CcSEcCtD
Solifenacin—Cough—Topiramate—obesity	0.000395	0.00103	CcSEcCtD
Solifenacin—Hypertension—Topiramate—obesity	0.00039	0.00102	CcSEcCtD
Solifenacin—Dizziness—Bupropion—obesity	0.000383	0.001	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000382	0.001	CcSEcCtD
Solifenacin—Dry mouth—Topiramate—obesity	0.000377	0.000987	CcSEcCtD
Solifenacin—Confusional state—Topiramate—obesity	0.000372	0.000976	CcSEcCtD
Solifenacin—Vomiting—Bupropion—obesity	0.000368	0.000966	CcSEcCtD
Solifenacin—Infection—Topiramate—obesity	0.000367	0.000961	CcSEcCtD
Solifenacin—Rash—Bupropion—obesity	0.000365	0.000958	CcSEcCtD
Solifenacin—Dermatitis—Bupropion—obesity	0.000365	0.000957	CcSEcCtD
Solifenacin—Headache—Bupropion—obesity	0.000363	0.000952	CcSEcCtD
Solifenacin—Nervous system disorder—Topiramate—obesity	0.000362	0.000949	CcSEcCtD
Solifenacin—Tachycardia—Topiramate—obesity	0.00036	0.000945	CcSEcCtD
Solifenacin—Skin disorder—Topiramate—obesity	0.000358	0.00094	CcSEcCtD
Solifenacin—Nausea—Bupropion—obesity	0.000344	0.000902	CcSEcCtD
Solifenacin—Somnolence—Topiramate—obesity	0.000328	0.00086	CcSEcCtD
Solifenacin—Dyspepsia—Topiramate—obesity	0.000325	0.000852	CcSEcCtD
Solifenacin—Decreased appetite—Topiramate—obesity	0.000321	0.000841	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Topiramate—obesity	0.000319	0.000836	CcSEcCtD
Solifenacin—Fatigue—Topiramate—obesity	0.000318	0.000834	CcSEcCtD
Solifenacin—Constipation—Topiramate—obesity	0.000316	0.000828	CcSEcCtD
Solifenacin—Feeling abnormal—Topiramate—obesity	0.000304	0.000797	CcSEcCtD
Solifenacin—Gastrointestinal pain—Topiramate—obesity	0.000302	0.000791	CcSEcCtD
Solifenacin—Urticaria—Topiramate—obesity	0.000293	0.000769	CcSEcCtD
Solifenacin—Abdominal pain—Topiramate—obesity	0.000292	0.000765	CcSEcCtD
Solifenacin—Hypersensitivity—Topiramate—obesity	0.000272	0.000713	CcSEcCtD
Solifenacin—Asthenia—Topiramate—obesity	0.000265	0.000694	CcSEcCtD
Solifenacin—Pruritus—Topiramate—obesity	0.000261	0.000685	CcSEcCtD
Solifenacin—Dizziness—Topiramate—obesity	0.000244	0.00064	CcSEcCtD
Solifenacin—Vomiting—Topiramate—obesity	0.000235	0.000615	CcSEcCtD
Solifenacin—Rash—Topiramate—obesity	0.000233	0.00061	CcSEcCtD
Solifenacin—Dermatitis—Topiramate—obesity	0.000232	0.00061	CcSEcCtD
Solifenacin—Headache—Topiramate—obesity	0.000231	0.000606	CcSEcCtD
Solifenacin—Nausea—Topiramate—obesity	0.000219	0.000575	CcSEcCtD
Solifenacin—CHRM1—Signaling Pathways—RPS6KB1—obesity	1.46e-05	5.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CAV1—obesity	1.46e-05	5.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FOXO1—obesity	1.46e-05	5.03e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RPS6KB1—obesity	1.46e-05	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APOA1—obesity	1.46e-05	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LPL—obesity	1.46e-05	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CD—obesity	1.46e-05	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IGF1—obesity	1.45e-05	5e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT2—obesity	1.45e-05	5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CB—obesity	1.45e-05	4.99e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FOXO1—obesity	1.45e-05	4.98e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RPS6KB1—obesity	1.44e-05	4.98e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CB—obesity	1.44e-05	4.97e-05	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—PIK3CA—obesity	1.44e-05	4.97e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SERPINE1—obesity	1.44e-05	4.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CB—obesity	1.43e-05	4.93e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LPA—obesity	1.42e-05	4.89e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TYK2—obesity	1.4e-05	4.83e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CD—obesity	1.39e-05	4.8e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RHOA—obesity	1.39e-05	4.79e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LPIN1—obesity	1.39e-05	4.78e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—PIK3CA—obesity	1.38e-05	4.76e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SERPINE1—obesity	1.38e-05	4.75e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3R1—obesity	1.38e-05	4.74e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOS3—obesity	1.38e-05	4.74e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOA5—obesity	1.36e-05	4.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PRKCD—obesity	1.36e-05	4.69e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PRKCD—obesity	1.36e-05	4.67e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PRKCD—obesity	1.34e-05	4.63e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TYK2—obesity	1.34e-05	4.62e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CG—obesity	1.33e-05	4.59e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR2A—obesity	1.33e-05	4.59e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RHOA—obesity	1.33e-05	4.58e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—C3—obesity	1.33e-05	4.58e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR2A—obesity	1.33e-05	4.57e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—C3—obesity	1.33e-05	4.56e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOS3—obesity	1.32e-05	4.54e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3R1—obesity	1.32e-05	4.54e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR2A—obesity	1.31e-05	4.53e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—C3—obesity	1.31e-05	4.52e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—PIK3CA—obesity	1.31e-05	4.51e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CLOCK—obesity	1.3e-05	4.47e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC22A1—obesity	1.3e-05	4.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PPARG—obesity	1.29e-05	4.43e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MTOR—obesity	1.27e-05	4.37e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CB—obesity	1.27e-05	4.37e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—POMC—obesity	1.27e-05	4.37e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GLP1R—obesity	1.27e-05	4.36e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SULT2A1—obesity	1.27e-05	4.36e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS2—obesity	1.26e-05	4.36e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGT—obesity	1.26e-05	4.35e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS2—obesity	1.26e-05	4.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—INS—obesity	1.26e-05	4.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGT—obesity	1.26e-05	4.34e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—PIK3CA—obesity	1.25e-05	4.32e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS2—obesity	1.25e-05	4.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGT—obesity	1.25e-05	4.3e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—DPYD—obesity	1.24e-05	4.29e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LEP—obesity	1.24e-05	4.26e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOE—obesity	1.24e-05	4.26e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LEP—obesity	1.23e-05	4.25e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOE—obesity	1.23e-05	4.25e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CAV1—obesity	1.23e-05	4.22e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOA1—obesity	1.22e-05	4.21e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CAV1—obesity	1.22e-05	4.21e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LEP—obesity	1.22e-05	4.21e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOE—obesity	1.22e-05	4.21e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOA1—obesity	1.22e-05	4.2e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CB—obesity	1.22e-05	4.19e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MTOR—obesity	1.22e-05	4.19e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CAV1—obesity	1.21e-05	4.17e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOA1—obesity	1.21e-05	4.16e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PRKAR2B—obesity	1.2e-05	4.13e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—DCN—obesity	1.19e-05	4.1e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ESR1—obesity	1.18e-05	4.07e-05	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AKT1—obesity	1.18e-05	4.06e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ESR1—obesity	1.18e-05	4.06e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CD—obesity	1.17e-05	4.03e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—F2—obesity	1.17e-05	4.02e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PRKCB—obesity	1.17e-05	4.02e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ESR1—obesity	1.17e-05	4.02e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—F2—obesity	1.16e-05	4.01e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PRKCB—obesity	1.16e-05	4.01e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—obesity	1.16e-05	4e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CPT1A—obesity	1.16e-05	3.99e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—obesity	1.16e-05	3.98e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BAD—obesity	1.15e-05	3.97e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PRKCB—obesity	1.15e-05	3.97e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—F2—obesity	1.15e-05	3.97e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BAD—obesity	1.15e-05	3.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BAD—obesity	1.14e-05	3.92e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NAMPT—obesity	1.13e-05	3.91e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—obesity	1.13e-05	3.89e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LIPC—obesity	1.13e-05	3.88e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCK—obesity	1.13e-05	3.88e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOC3—obesity	1.12e-05	3.86e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CG—obesity	1.12e-05	3.85e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CG—obesity	1.11e-05	3.84e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—obesity	1.11e-05	3.83e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—NOS3—obesity	1.11e-05	3.81e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3R1—obesity	1.11e-05	3.81e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS1—obesity	1.1e-05	3.8e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—obesity	1.1e-05	3.8e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CG—obesity	1.1e-05	3.8e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS1—obesity	1.1e-05	3.79e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS1—obesity	1.09e-05	3.75e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CETP—obesity	1.09e-05	3.75e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SDC1—obesity	1.08e-05	3.71e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MAPK8—obesity	1.07e-05	3.7e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—obesity	1.07e-05	3.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—POMC—obesity	1.06e-05	3.66e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—POMC—obesity	1.06e-05	3.65e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKR1C3—obesity	1.06e-05	3.65e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—INS—obesity	1.06e-05	3.64e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—obesity	1.06e-05	3.64e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—INS—obesity	1.05e-05	3.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—POMC—obesity	1.05e-05	3.62e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—INS—obesity	1.04e-05	3.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SCARB1—obesity	1.04e-05	3.59e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL2—obesity	1.04e-05	3.58e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL2—obesity	1.04e-05	3.57e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MAPK8—obesity	1.03e-05	3.54e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL2—obesity	1.03e-05	3.54e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—obesity	1.02e-05	3.53e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF1—obesity	1.02e-05	3.52e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT2—obesity	1.02e-05	3.52e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CB—obesity	1.02e-05	3.51e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF1—obesity	1.02e-05	3.51e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT2—obesity	1.02e-05	3.51e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SREBF1—obesity	1.01e-05	3.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—obesity	1.01e-05	3.48e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF1—obesity	1.01e-05	3.48e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT2—obesity	1.01e-05	3.47e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GOT2—obesity	9.84e-06	3.39e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CD—obesity	9.82e-06	3.38e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STAT3—obesity	9.81e-06	3.38e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CD—obesity	9.79e-06	3.37e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CA—obesity	9.73e-06	3.35e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SERPINE1—obesity	9.71e-06	3.35e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CA—obesity	9.7e-06	3.34e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CD—obesity	9.7e-06	3.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SERPINE1—obesity	9.68e-06	3.33e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—FASN—obesity	9.63e-06	3.32e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CA—obesity	9.6e-06	3.31e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—BCHE—obesity	9.59e-06	3.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SERPINE1—obesity	9.59e-06	3.3e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TYK2—obesity	9.45e-06	3.25e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TYK2—obesity	9.42e-06	3.24e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STAT3—obesity	9.4e-06	3.24e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RHOA—obesity	9.37e-06	3.23e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RHOA—obesity	9.34e-06	3.22e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TYK2—obesity	9.33e-06	3.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOS3—obesity	9.27e-06	3.19e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3R1—obesity	9.27e-06	3.19e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2E1—obesity	9.25e-06	3.19e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RHOA—obesity	9.25e-06	3.19e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOS3—obesity	9.24e-06	3.18e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3R1—obesity	9.24e-06	3.18e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3R1—obesity	9.15e-06	3.15e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOS3—obesity	9.15e-06	3.15e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NQO1—obesity	9.15e-06	3.15e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—obesity	9.12e-06	3.14e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—obesity	9.09e-06	3.13e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CA—obesity	8.83e-06	3.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CA—obesity	8.81e-06	3.03e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCG—obesity	8.77e-06	3.02e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A4—obesity	8.77e-06	3.02e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—obesity	8.73e-06	3.01e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CA—obesity	8.72e-06	3e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—obesity	8.71e-06	3e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYCS—obesity	8.66e-06	2.98e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MTOR—obesity	8.56e-06	2.95e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CB—obesity	8.56e-06	2.95e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MTOR—obesity	8.53e-06	2.94e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CB—obesity	8.53e-06	2.94e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GOT1—obesity	8.49e-06	2.93e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GGT1—obesity	8.49e-06	2.93e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MTOR—obesity	8.45e-06	2.91e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CB—obesity	8.45e-06	2.91e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA1—obesity	8.37e-06	2.88e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—STK11—obesity	8.25e-06	2.84e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP19A1—obesity	8.25e-06	2.84e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—obesity	7.95e-06	2.74e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—obesity	7.92e-06	2.73e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—obesity	7.84e-06	2.7e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—obesity	7.82e-06	2.69e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—obesity	7.8e-06	2.69e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CA—obesity	7.74e-06	2.67e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—obesity	7.72e-06	2.66e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—COMT—obesity	7.67e-06	2.64e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GNB3—obesity	7.56e-06	2.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARGC1A—obesity	7.56e-06	2.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMOX1—obesity	7.53e-06	2.59e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—obesity	7.44e-06	2.56e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—obesity	7.42e-06	2.55e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CA—obesity	7.41e-06	2.55e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GNAS—obesity	7.36e-06	2.53e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—obesity	7.35e-06	2.53e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK8—obesity	7.24e-06	2.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—obesity	7.22e-06	2.49e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK8—obesity	7.21e-06	2.48e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOB—obesity	7.21e-06	2.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—obesity	7.19e-06	2.48e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK8—obesity	7.14e-06	2.46e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—obesity	7.12e-06	2.45e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LPL—obesity	6.88e-06	2.37e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—obesity	6.85e-06	2.36e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPX1—obesity	6.71e-06	2.31e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STAT3—obesity	6.62e-06	2.28e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STAT3—obesity	6.59e-06	2.27e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—obesity	6.56e-06	2.26e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CD36—obesity	6.54e-06	2.25e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STAT3—obesity	6.53e-06	2.25e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—obesity	6.32e-06	2.18e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CA—obesity	6.22e-06	2.14e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTHFR—obesity	6.2e-06	2.13e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—obesity	6.15e-06	2.12e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—obesity	6.13e-06	2.11e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—obesity	6.13e-06	2.11e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—obesity	6.11e-06	2.11e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARA—obesity	6.08e-06	2.09e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—obesity	6.07e-06	2.09e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—obesity	6.05e-06	2.09e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—obesity	6.05e-06	2.08e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AGT—obesity	5.89e-06	2.03e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOE—obesity	5.77e-06	1.99e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CAV1—obesity	5.72e-06	1.97e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOA1—obesity	5.7e-06	1.96e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CA—obesity	5.22e-06	1.8e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CG—obesity	5.21e-06	1.79e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CA—obesity	5.2e-06	1.79e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CA—obesity	5.15e-06	1.77e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—obesity	5.08e-06	1.75e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARG—obesity	5.03e-06	1.73e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—POMC—obesity	4.96e-06	1.71e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—INS—obesity	4.93e-06	1.7e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—obesity	4.62e-06	1.59e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—obesity	4.61e-06	1.59e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CD—obesity	4.58e-06	1.58e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—obesity	4.56e-06	1.57e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—obesity	4.52e-06	1.56e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3R1—obesity	4.32e-06	1.49e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NOS3—obesity	4.32e-06	1.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—obesity	4.26e-06	1.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—obesity	4.25e-06	1.46e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—obesity	4.21e-06	1.45e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CB—obesity	3.99e-06	1.37e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—obesity	3.95e-06	1.36e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CA—obesity	2.43e-06	8.38e-06	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—obesity	1.99e-06	6.84e-06	CbGpPWpGaD
